© ACCESS Newswire
09.12.2025
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms
News Preview
MESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce a marked rise in trading activity and shareholder engagement as the Company transitions into a new phase of technology-driven growth and leaves behind dilution tied to its previous Regulation A offering. Over recent trading se...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
IGC
LISTED
XASE
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
News Preview
POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced it has reached a key enrollment milestone of 65% for its...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
PTIX
LISTED
NASDAQ
Results from Phase 1 Multiple-Dose Study of PT00114
News Preview
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target the biology of chronic stress and its downstream...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
09.12.2025
APVO
LISTED
NASDAQ
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
News Preview
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care SEATTLE, WA / ACCESS Newswire / December 9, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
09.12.2025
AIML
LISTED
CSE
AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield(TM) and Insight360(TM) into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem
News Preview
This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration.Partnership positions MaxYield™ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform. TORON...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
News Preview
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
ROG
LISTED
SIX
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
News Preview
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
ROG
LISTED
SIX
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
News Preview
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis. These disease classifications de...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
XPHY
LISTED
CSE
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
News Preview
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's proprietary oral dissolvable film (ODF) drug-delivery system. The...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
9926
LISTED
HKSE
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
News Preview
HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by Professor Shun Lu from Shanghai Chest Hospital. The study evaluates ivonescimab (a first-in-class PD-1/...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ALGN
LISTED
NASDAQ
Align Technology Announces Invisalign® System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction
News Preview
Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced commercial availability in Thailand of the Invisalign System with...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
SOL
LISTED
CSE
SOL Global Announces Share Consolidation
News Preview
Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors has resolved to complete a share consolidation (the "Consolidation") of its issued and outstanding common shares (each, a "Pre-Consolida...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
09.12.2025
9969
LISTED
HKSE
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
News Preview
The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster....
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
DOSE
LISTED
CSE
Rapid Dose Completes Extension to Promissory Notes
News Preview
Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it has extended the maturity date of its outstanding secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing") which closed in 2023. The Not...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
1801
LISTED
HKSE
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
6855
LISTED
HKSE
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced tha...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
6855
LISTED
HKSE
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced th...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
6855
LISTED
HKSE
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced th...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
BIOA B
LISTED
STO
Leqembi included in China's commercial insurance innovative drug list
News Preview
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
BIOA B
LISTED
STO
Leqembi included in China's commercial insurance innovative drug list
News Preview
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
TRUL
LISTED
CSE
Trulieve Announces US$100 Million Private Placement of 10.5% Senior Secured Notes
News Preview
TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has received commitments for a private placement of 10.5% Senior Secured Notes due 2030 (the "Notes") for aggregate gross proceeds of US...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
TRUL
LISTED
CSE
Trulieve Announces US$100 Million Private Placement of 10.5% Senior Secured Notes
News Preview
TALLAHASSEE, Fla., Dec. 8, 2025 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has received commitments for a private placement of 10.5% Senior Secured Notes due 2030 (the "Notes") for aggregate gross proceeds of US$100.0...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
BIIB
LISTED
NASDAQ
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
News Preview
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generi...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
CRNO B
LISTED
STO
Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)
News Preview
GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to initiate the company's Phase II...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
CRNO B
LISTED
STO
Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)
News Preview
GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to initiate the company's Phase II...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
INCY
LISTED
NASDAQ
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
News Preview
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, as a treatment for patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). These data, which are featured in o...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting.
Highlights include updates from the company’s targeted protein degradation pipeline, including data on first-in-class investigational lymph...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
GMAB
LISTED
NASDAQ
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
News Preview
Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transfor...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
BKD
LISTED
NYSE
Brookdale Reports November 2025 Occupancy
News Preview
NASHVILLE, Tenn., Dec. 8, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for November 2025.November 2025 ObservationsNovember consolidated occupancy results:Weighted average occupancy of 82.5% increased 300 basis points year-over-year and decreased 10 basis points sequentially.Historical seq...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
HIK
LISTED
LSE
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
News Preview
Ready-to-use sepsis therapy marks new advancement in time-critical treatmentLONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin i...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
PACS
LISTED
NYSE
PACS Group Expands Management Team, Adding New Chief Compliance Officer and Chief Human Resource Officer to Executive Leadership Team
News Preview
PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announces the appointments of Kelly Priegnitz as Chief Compliance Officer and Trent Bingham as Chief Human Resources Officer. Mr. Bingham joined PACS on Nov. 10, while Ms. Priegni...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
HALO
LISTED
NASDAQ
Jim Lang Elected to Halozyme's Board of Directors
News Preview
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics."Jim brings extensive experience in building and...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ABCL
LISTED
NASDAQ
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
News Preview
AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the prese...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
PHR
LISTED
NYSE
Phreesia Announces Third Quarter Fiscal 2026 Results and Introduces Fiscal 2027 Outlook
News Preview
Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2025.
“I am very proud of our team’s strong execution in the fiscal third quarter, which is reflected throughout this letter from our revenue and profit results to product updates and client stories,” said CEO...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
MRMD
LISTED
CSE
Veterans Healing Journey Becomes Soundtrack of Thrive Dispensaries
News Preview
Veteran and customer of Thrive Dispensary in Anna, IL writes song of appreciation for Thrive and to raise visibility for veteran's org FreedomSingsUSA....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GMAB
LISTED
CPH
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ROG
LISTED
SIX
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
News Preview
Basel, 8 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different types of lymphoma, presented at the 67th American Society of Hematology Annual Meeting and Exposition, 6-9 December 2025 in Orlando, Florida, US....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ACHV
LISTED
NASDAQ
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
News Preview
SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that the company has issued inducement grants of stock...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
ASMB
LISTED
XETRA
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re
News Preview
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study –...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
TARA
LISTED
NASDAQ
Protara Announces Closing of $75 Million Public Offering
News Preview
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $5.75...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
CRDF
LISTED
NASDAQ
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
News Preview
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be prese...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
News Preview
Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
News Preview
WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne a...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Proposed Public Offering
News Preview
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
GPCR
LISTED
NASDAQ
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
News Preview
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other c...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
News Preview
Vera Therapeutics announces proposed public offering of Class A common stock....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
FULC
LISTED
NASDAQ
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
News Preview
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $150.0 millio...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
WVE
LISTED
NASDAQ
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
News Preview
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today that it has commenced an underwritten public offering of $250 million in aggregate o...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
LLY
LISTED
NYSE
Lilly declares first-quarter 2026 dividend
News Preview
INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026.About LillyLilly is a medicine...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
TVGN
LISTED
NASDAQ
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
News Preview
WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey’s economic and innovation landscape....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
TERN
LISTED
NASDAQ
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
News Preview
64% MMR achievement by 24 weeks across all efficacy evaluable patients ...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ATYR
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This press rel...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
STAA
LISTED
NASDAQ
Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
News Preview
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us,” or “our”) today issued the following open letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the proposed sale of the Company to Alcon...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.12.2025
BHC
LISTED
TSX
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
News Preview
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the results to date of its previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the &qu...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
CODX
LISTED
NASDAQ
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
News Preview
Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing
SALT LAKE CITY, Dec. 8, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the developm...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
MAAT
LISTED
EURONEXT
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
News Preview
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that Prof. Malard, MD, PhD, hematology professor at Saint-Antoine Hospit...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TR...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
IPN
LISTED
EURONEXT
Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
News Preview
Monthly information relative to the total number of voting rights and shares composing the share capital...
Themefolio
Profiler
Peergroup
© PR Newswire
08.12.2025
YCBD
LISTED
XASE
cbdMD, Inc. Regains Compliance with NYSE American Listing Standards
News Preview
CHARLOTTE, N.C., Dec. 8, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leading innovator in wellness and hemp-derived products, is pleased to announce that it has regained full compliance with the continued listing standards of the NYSE American. As a result, the ".BC" indicator has been removed from the list of noncompliant issuers ef...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
